CPA
KRYS icon

Capital Performance Advisors’s Krystal Biotech KRYS Stock Holding History

Capital Performance Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4
Closed -$728 – 1495
2024
Q3 		$728 Buy
+4
New +$771 ﹤0.01% 2073

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital Performance Advisors's KRYS Position: Q4 2024 in Review

Capital Performance Advisors sold out of Krystal Biotech (KRYS) in Q4 2024, closing a stake of 4 shares — an estimated $728 sold.

Capital Performance Advisors first reported a position in KRYS in Q3 2024 and held it in 1 quarter. The position peaked at $728 in Q3 2024. 264 funds tracked by Wall St. Rank hold KRYS as of Q4 2024.

  • Capital Performance Advisors reported no remaining Krystal Biotech position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 4 Krystal Biotech shares in Q4 2024, an estimated $728.
  • Capital Performance Advisors first reported a position in Krystal Biotech in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Krystal Biotech position peaked at $728 in Q3 2024.
  • 264 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.